Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan to expand operations in Ireland
Through the investment, Mylan is expected to add more than 500 new positions to its Ireland-based workforce by 2016. The company’s investment will include funding for expanded research
Through the investment, Mylan is expected to add more than 500 new positions to its Ireland-based workforce by 2016. The company’s investment will include funding for expanded research
The company now confirms that the $15m milestone associated with its licensing and development agreement with Endo Pharmaceuticals for BEMA Buprenorphine is payable. With this the total milestone
Discovered and developed by Sunovion Pharmaceuticals, Lunesta is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic). In a Phase II/III study (Study 126) conducted in Japan, patients treated
B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level. The characterization gives a detailed reading of immune responses in
The patent contains pharmaceutical composition claims covering NewLink’s HyperAcute products for the treatment of cancer. NewLink holds exclusive rights to the allowed application as well as to previously
IB1001 is an intravenous recombinant factor IX (rFIX) protein, and has completed pivotal Phase 3 clinical studies that support the filling of the BLA. Inspiration will receive a
LCIG is administered via a procedurally-implanted tube connected to a portable pump which delivers the medication directly into the small intestine, providing a continuous delivery of medication during
Rockland will market LDI’s portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.
The trial is designed to evaluate the safety and efficacy of sustained erythropoietin (EPO) therapy delivered via the company’s EPODURE Biopump for the treatment of anemia in dialysis
IMO-3100 is an immunomodulator that inhibits the activity of TLR7 and TLR9 and modulates the production of multiple pro-inflammatory mediators. The randomized, double-blind, and placebo-controlled study is designed